Journal of Infectious Disease and Pathology
Open Access

Bacteriophages; Phage therapy; Infectious diseases; Antibiotic resistance; Precision medicine; Biofilm disruption

Introduction

In the world of infectious diseases, the emergence of antibioticresistant bacteria has posed a significant threat to public health. The overuse and misuse of antibiotics have fueled the rise of these superbugs, rendering many conventional treatments ineffective. In this era of antibiotic resistance, scientists and healthcare professionals are turning to a century-old yet remarkably modern solution: bacteriophages. Bacteriophages, or simply phages, are viruses that infect and destroy bacteria. Their unique ability to target and kill specific bacterial strains makes them an intriguing alternative to antibiotics. In this article, we'll explore the contemporary applications of bacteriophages in treating infectious diseases, shedding light on their potential to revolutionize the field of medicine [1]. The history of phage therapy dates back to the early 20th century when it was first developed as a means of treating bacterial infections. However, the advent of antibiotics in the mid-20th century led to a decline in the popularity of phage therapy. In recent years, the relentless spread of antibiotic resistance has rekindled interest in these microscopic warriors. Researchers and medical practitioners are now exploring and leveraging the contemporary applications of bacteriophages in the treatment of infectious diseases [2].

This article delves into the various ways bacteriophages are being applied in modern medicine, highlighting their precision, personalized treatment potential, and effectiveness against antibiotic-resistant bacteria. We will also discuss their capacity to disrupt bacterial biofilms and present real-world success stories that underscore their utility. However, we must also address the challenges that come with the resurgence of phage therapy, including regulatory issues and the necessity for a deeper understanding of phage biology. The resurgence of phage therapy Phage therapy, the use of bacteriophages to combat bacterial infections, is not a new concept. It was first developed in the early 20th century but lost prominence with the advent of antibiotics. However, the rise of antibiotic resistance has rekindled interest in phage therapy, prompting extensive research into its applications [3].

Targeted precision

One of the most significant advantages of bacteriophages is their specificity. Each type of phage is highly selective, infecting only a particular bacterial strain while leaving human cells unharmed. This specificity minimizes collateral damage and reduces the risk of antibiotic-resistant strains emerging. Personalized medicine Phage therapy can be tailored to individual patients. Unlike antibiotics, which are broad-spectrum and may not work against a specific bacterial infection, phages can be isolated and tested to find the most effective match for a patient's particular strain of bacteria. This personalized approach enhances the likelihood of successful treatment [4].

Biofilm disruption

Biofilms, protective layers formed by bacteria, can be impervious to antibiotics. Bacteriophages, however, have shown promise in penetrating and disrupting these biofilms, making them useful in the treatment of chronic and persistent infections. Combating antibiotic-resistant infections Phage therapy is especially valuable in the fight against antibioticresistant bacteria. As the efficacy of many antibiotics wanes, phages offer an alternative that is less likely to encounter resistance, making them a lifeline in the battle against superbugs [5].

Challenges and future directions While bacteriophages hold great promise, they are not without challenges. One key concern is the regulation of phage therapy, ensuring the safety and efficacy of treatments. Research is ongoing to address these regulatory issues and streamline the approval process for phage-based treatments [6]. Another challenge is the need for a deep understanding of phage biology, including the interactions between phages and bacteria. Researchers are working to expand our knowledge of these complex relationships to optimize phage therapy protocols. Real-world success stories In countries like Georgia and Poland, phage therapy has been used successfully for decades, treating a range of bacterial infections. In the United States and other countries, clinical trials and case studies have demonstrated the potential of phage therapy in treating patients with infections that resist all available antibiotics [7].

Discussion

One of the key strengths of bacteriophages is their exceptional specificity. Each type of phage is highly selective, infecting only a particular strain of bacteria while sparing others, including human cells. This precision reduces collateral damage, making phage therapy a promising alternative to the often non-specific action of antibiotics. As a result, phage therapy can be used to treat infections without disturbing the body's natural microbiota [8].

Phage therapy can be personalized to an individual patient's specific bacterial infection. Unlike antibiotics, which are generally broad-spectrum and may not effectively combat a particular bacterial strain, phages can be isolated, tested, and matched to the patient's infection. This tailored approach increases the likelihood of successful treatment outcomes, particularly in cases where standard antibiotics have failed. Bacterial biofilms, protective layers that bacteria form on surfaces, are often impervious to antibiotics. Phages, on the other hand, have demonstrated their ability to penetrate and disrupt these biofilms [9,10]. This feature is of particular significance in the treatment of chronic and persistent infections, where biofilms play a significant role in pathogenesis.

Phage therapy is gaining attention as a valuable approach in the fight against antibiotic-resistant bacteria, commonly referred to as superbugs. These resistant strains are on the rise, rendering many traditional antibiotics ineffective. Bacteriophages offer a potential solution, as they are less likely to encounter resistance due to their specific targeting mechanism.

To fully harness the potential of phage therapy, researchers must deepen their understanding of phage biology and the intricate interactions between phages and bacteria. This knowledge will help optimize treatment protocols and identify the most effective phages for specific infections. Phage therapy has been employed successfully in several countries for decades, including Georgia and Poland, where it has been an integral part of the healthcare system. Additionally, clinical trials and case studies in the United States and other countries have demonstrated the potential of phage therapy in treating patients with infections that resist all available antibiotics, showcasing its real-world efficacy.

Conclusion

Bacteriophages, with their precision and adaptability, are becoming a powerful tool in the fight against infectious diseases. The resurgence of phage therapy offers hope in a world where antibiotic resistance has created dire medical challenges. As ongoing research and clinical trials continue to shed light on the potential of phage therapy, it is possible that these tiny but mighty viruses may become a cornerstone of modern medicine, ushering in a new era of infectious disease treatment. As phage therapy has attracted the attention of clinicians and scholars again, its advantages and disadvantages are also known. .e advantages of phage therapy are as follows: first, phage specificity is high. General antibiotics are relatively broad-spectrum and the elimination of target pathogens by them also causes destruction of other symbiotic microbiota. .us, long-term use of antibiotics is not only easy to cause microbiota disturbance but may also lead to opportunistic infection. However, phages can specifically infect host bacteria without affecting other symbiotic microbiota; second, phages have low resistance to bacteria.

Acknowledgement

None

Conflict of Interest

None

1. Zimecki M, Artym J, Kocięba M, Weber-Dąbrowska B, et al. (2009) Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus.BMC Microbiol 9: 169.

Indexed at, Google Scholar, Crossref

2. Matsuda T, Freeman TA, Hilbert DW (2005) Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model.Surgery 137: 639–646.

Indexed at, Google Scholar, Crossref

3. Speck P, Smithyman A (2016) Safety, and efficacy of phage therapy via the intravenous route.FEMS Microbiol Lett 363: 242.

Indexed at, Google Scholar, Crossref

4. Hietala V, Horsma-Heikkinen J, Carron A, Skurnik M, Kiljunen S (2019) The removal of endo- and enterotoxins from bacteriophage preparations.Front Microbiol 10: 1674.

Indexed at, Google Scholar, Crossref

5. Loh B, Gondil VS, Manohar P, Khan FM, Yang H, et al. (2020)Encapsulation and delivery of therapeutic phages.Appl Environ Microbiol 87: 01979-02020.

Indexed at, Google Scholar, Crossref

6. Melnyk AH, Wong A, Kassen R (2015) The fitness costs of antibiotic resistance mutations.Evol Appl 8: 273–283.

Indexed at, Google Scholar, Crossref

7. Yacoby I, Shamis M, Bar H, Shabat D, Benhar I (2006) Targeting antibacterial agents by using drug-carrying filamentous bacteriophages.Antimicrob Agents Chemother 50: 2087–2097.

Indexed at, Google Scholar, Crossref

8. Gibb B, Hyman P, Schneider CL (2021) The many applications of engineered bacteriophages – An overview.Pharmaceuticals 14: 634.

Indexed at, Google Scholar, Crossref

9. Goswami A, Sharma PR, Agarwal R (2021) Combatting intracellular pathogens using bacteriophage delivery.Crit Rev Microbiol 47: 461–478.

Indexed at, Google Scholar, Crossref

10. Staquicini DI, Tang FHF, Markosian C (2021) Design and proof-of-concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain.Proc Natl Acad Sci USA 118: 2105739118.

Indexed at, Google Scholar, Crossref